Investigational drug · Phase 3
Amlenetug
Also called: Lu AF82422
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple System Atrophy.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
1
Any phase or sponsor naming "Amlenetug"
First trial start
2021
Nov 16, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Amlenetug", any sponsor or status.
Conditions studied
As listed on its trial records.
- Multiple System Atrophy
Largest trials
Live from ClinicalTrials.gov: studies naming "Amlenetug" as an intervention, largest first.
- A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)Pivotal-lookingActive, not recruiting
H. Lundbeck A/SIndustry
NCT06706622 · 401 participants · Start Dec 3, 2024 · Primary completion Feb 17, 2028
Drug: Amlenetug; Placebo · For: Multiple System Atrophy
Sites: Phoenix, Arizona; Little Rock, Arkansas; San Francisco, California · 74 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The Efficacy and Safety of Monoclonal Antibodies That Target Alpha-Synuclein in Parkinson's Disease: A Systematic Review.
Coles D, Kalyana A, Khalil S, et al. · Parkinsons Dis 2026
- Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial.
Kjærsgaard L, Wiedemann J, Singer W, et al. · Lancet Neurol 2026
- Immunotherapy in Early Parkinson's Disease: A Biomarker-Driven Trial Framework for Secondary Prevention.
Kniazev R · Cureus 2025
- Comparative assessment of binding and functional differences of clinical antibodies targeting α-synuclein in cellular models of Parkinson's disease.
Liu Y, Dalkilic-Liddle I, Li Y, et al. · Biomed Pharmacother 2025
- Rational selection of the monoclonal α-synuclein antibody amlenetug (Lu AF82422) for the treatment of α-synucleinopathies.
Kallunki P, Sotty F, Willén K, et al. · NPJ Parkinsons Dis 2025
- An update on immune-based alpha-synuclein trials in Parkinson's disease.
Alfaidi M, Barker RA, Kuan WL · J Neurol 2024
Also in development for Multiple System Atrophy
- PBT434ATH434Phase 23 trials
Alterity Therapeutics · Multiple System Atrophy
- Foralumab NasalPhase 22 trials
Tiziana Life Sciences LTD · ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis, ALS
- TEV-56286EmrusolminPhase 22 trials
Teva · Multiple System Atrophy
- exidavnemabPhase 21 trial
BioArctic AB · Parkinson Disease, Multiple System Atrophy
- TAK-341MEDI1341Phase 21 trial
Takeda · Multiple System Atrophy
- YA-101Phase 21 trial
Dasher Neuroscience Inc. · Multiple System Atrophy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.